Surgery and chemotherapy are associated with improved overall survival in anal adenocarcinoma: results of a national cohort study
- 141 Downloads
Anal adenocarcinoma (AAC) is a rare disease with treatment protocols that mimic both that of rectal adenocarcinoma (RAC) and anal squamous cell carcinoma (ASCC). Due to its rarity, data regarding outcomes are lacking. We sought to determine outcomes of patients with AAC compared to RAC and ASCC and to evaluate risk factors for mortality in AAC.
The United States’ National Cancer Database was queried for all adult patients presenting with nonmetastatic AAC, RAC, or ASCC from 2003 to 2011. The primary outcome was overall survival. Intergroup univariate comparisons, unadjusted Kaplan-Meier, and multivariable Cox proportional hazards modeling were used to compare outcomes between AAC, RAC, and ASCC and to identify factors associated with survival within AAC.
The query identified 129,153 patients (N = 2117 AAC, 19,427 ASC, 107,609 RAC). AAC patients were less likely than RAC patients to have surgery (72.5 vs. 87.1%), and also less likely to receive chemotherapy (54.7% vs. 96.1%) and radiation (58.2% vs. 74.1%) than patients with ASCC (all p < 0.001). Overall median survival in AAC was 65 months compared to 109 months for RAC and > 120 months for ASCC. On multivariable analysis, independent treatment-related predictors of decreased mortality hazard in AAC included proctectomy (hazard ratio [HR], 0.66) and chemotherapy (HR, 0.60) (both p < 0.001).
AAC tumors have worse prognosis than either RAC or ASCC. Within patients with AAC, nonsurgical management was independently associated with increased mortality hazard. Patients with AAC should be evaluated in a multidisciplinary setting and referred for surgery.
KeywordsAnal cancer Adenocarcinoma Outcomes
The NCDB is a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The data used in the study are derived from a de-identified NCDB participant user file. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methods or the conclusions drawn from these data by the investigators.
This work has been supported indirectly by the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery and by the Mayo School of Graduate Medical Education Clinician Investigator program. No specific grant number is associated with the work.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
- 3.Stewart DB, Gaertner WB, Glasgow SC, Herzig DO, Feingold D, Steele SR, Prepared on Behalf of the Clinical Practice Guidelines Committee of the American Society of C, Rectal S (2018) The American society of colon and rectal surgeons clinical practice guidelines for anal squamous cell cancers (revised 2018). Dis Colon rectum 61(7):755–774. https://doi.org/10.1097/DCR.0000000000001114
- 4.Monson JR, Weiser MR, Buie WD, Chang GJ, Rafferty JF, Buie WD, Rafferty J, Standards Practice Task Force of the American Society of C, Rectal S (2013) Practice parameters for the management of rectal cancer (revised). Dis Colon rectum 56(5):535–550. https://doi.org/10.1097/DCR.0b013e31828cb66c
- 5.Chang GJ, Gonzalez RJ, Skibber JM, Eng C, Das P, Rodriguez-Bigas MA (2009) A twenty-year experience with adenocarcinoma of the anal canal. Dis Colon rectum 52(8):1375–1380. https://doi.org/10.1007/DCR.0b013e3181a79589
- 6.Beal KP, Wong D, Guillem JG, Paty PB, Saltz LL, Wagman R, Minsky BD (2003) Primary adenocarcinoma of the anus treated with combined modality therapy. Dis Colon rectum 46(10):1320–1324. https://doi.org/10.1097/01.DCR.0000089116.17611.07
- 7.Bertelson N, Blumetti J, Cintron J, Harrison J, Chaudhry V, Abcarian H (2015) Anal adenocarcinoma: outcomes in an uncommon malignancy. Am Surg 81(11):1114–1117Google Scholar
- 15.Belkacemi Y, Berger C, Poortmans P, Piel G, Zouhair A, Meric JB, Nguyen TD, Krengli M, Behrensmeier F, Allal A, De Looze D, Bernier J, Scandolaro L, Mirimanoff RO, Rare Cancer N (2003) Management of primary anal canal adenocarcinoma: a large retrospective study from the Rare Cancer Network. Int J Radiat Oncol Biol Phys 56(5):1274–1283CrossRefGoogle Scholar
- 16.Longo WE, Vernava AM 3rd, Wade TP, Coplin MA, Virgo KS, Johnson FE (1995) Rare anal canal cancers in the U.S. veteran: patterns of disease and results of treatment. Am Surg 61(6):495–500Google Scholar